3/15
05:26 pm
tlx
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Low
Report
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
3/15
05:25 pm
tlx
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
Low
Report
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
3/15
01:05 am
tlx
Low
Report
3/9
07:19 pm
tlx
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Low
Report
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
3/9
06:34 pm
tlx
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
Medium
Report
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
3/7
02:59 am
tlx
Low
Report
3/1
10:52 pm
tlx
Telix Pharmaceuticals Highlights $1B Revenue Track, Pixclara Resubmission, PSMA Growth at Oppenheimer Conf. [Yahoo! Finance]
Low
Report
Telix Pharmaceuticals Highlights $1B Revenue Track, Pixclara Resubmission, PSMA Growth at Oppenheimer Conf. [Yahoo! Finance]
3/1
05:57 pm
tlx
Investor Education Webinar
Low
Report
Investor Education Webinar
3/1
05:56 pm
tlx
Investor Education Webinar
Low
Report
Investor Education Webinar
2/27
07:00 am
tlx
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
Low
Report
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
2/26
06:01 am
tlx
1 Basically Unknown Stock That Could Turn Cancer-Imaging Breakthroughs Into Generational Wealth [Yahoo! Finance]
Medium
Report
1 Basically Unknown Stock That Could Turn Cancer-Imaging Breakthroughs Into Generational Wealth [Yahoo! Finance]
2/24
07:01 am
tlx
Telix Pharmaceuticals (NASDAQ:TLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Telix Pharmaceuticals (NASDAQ:TLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/20
07:00 am
tlx
Telix to Participate in Oppenheimer and TD Cowen Conferences
Medium
Report
Telix to Participate in Oppenheimer and TD Cowen Conferences
2/19
07:02 pm
tlx
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
High
Report
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
2/19
06:27 pm
tlx
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
High
Report
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
2/17
04:55 pm
tlx
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
Low
Report
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
2/17
04:54 pm
tlx
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
Low
Report
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
2/7
02:07 am
tlx
Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by analysts at
Wall Str
Low
Report
Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by analysts at
Wall Str
2/3
04:38 pm
tlx
Telix Full Year Results 2025 Investor Webcast Notification
Low
Report
Telix Full Year Results 2025 Investor Webcast Notification
2/3
04:35 pm
tlx
Telix Full Year Results 2025 Investor Webcast Notification
Low
Report
Telix Full Year Results 2025 Investor Webcast Notification
1/28
06:43 pm
tlx
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
Medium
Report
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
1/27
08:44 am
tlx
Telix Pharmaceuticals (NASDAQ:TLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Telix Pharmaceuticals (NASDAQ:TLX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
1/24
12:30 am
tlx
Telix Pharmaceuticals (NASDAQ:TLX) was upgraded by analysts at
Wall Stree
Low
Report
Telix Pharmaceuticals (NASDAQ:TLX) was upgraded by analysts at
Wall Stree
1/21
08:00 am
tlx
Telix Pharmaceuticals (NASDAQ:TLX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Telix Pharmaceuticals (NASDAQ:TLX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
1/20
07:00 am
tlx
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
Low
Report
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch